OA04. 06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)

LAH Douma, CJ De Gooijer, V Noort, F Lalezari… - Journal of Thoracic …, 2022 - jto.org
Methods PEMMELA was a prospective single-center, single-arm, open-label, investigator-
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus …
被引用次数：3 相关文章

OA04. 06 PEMbrolizumab Plus Lenvatinib In Second And Third Line Malignant Pleural MEsotheLiomA Patients: A Single Arm Phase II Study (PEMMELA)

LAH Douma, CJ de Gooijer, V Noort, F Lalezari… - Journal of Thoracic …, 2022 - Elsevier
Methods PEMMELA was a prospective single-center, single-arm, open-label, investigator-
initiated phase 2 trial of pembrolizumab (200 mg once every three weeks intravenously) plus …